Hillevax — Investor Presentation (January 2024)
23 slides from Hillevax's investor presentation, Jan 8, 2024
Slide 1: Corporate presentation January 2024
Corporate presentation January 2024 Exhibit 99.1
Slide 2: Forward-looking statements
We caution you that this presentation contains forward-looking statements of HilleVax, Inc. (“HilleVax,” “we,” “us” or similar terms). All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financia
Slide 3: HilleVax investment highlights
HilleVax January 2024 Norovirus has a high disease burden and unmet need Clinical PoC demonstrated in adults and near-term large Phase IIb infant readout in mid-2024 Multi-billion dollar commercial opportunity Strong capital position with $324.4M in cash at September 30, 2023
Slide 4: Norovirus in the news
“And these symptoms can be quite severe too. Norovirus often isn’t just your typical I’m-feeling-a-little-sick-so-I-may-pass-on-shuffleboard type of gastroenteritis. No, a norovirus infection can consist of projectile vomiting and explosive diarrhea. Projecting your voice, feelings, or insecurities
Slide 5: Norovirus global annual burden is high
1. Bartsch et al., 2016 2. Bartsch et al., 2020 Norovirus global annual burden is high… Direct Medical Clinical management, hospitalizations, infection control measures and cleaning, surveillance Indirect Health Productivity losses: sick staff work days, resources not used while managing outbreak Co
Slide 6: GII.4 remains the dominant genotype worldwide
1 Cannon et al. Emerg Infect Dis. 2021.; 2 Fang et al. BMC Infect Dis. 2021.; 3 Lo et al. Arch Virol. 2021.; 4 Cho et al. J Med Virol. 2021.; 5 Rossouw et al. Viruses. 2021.; 6 Manouana et al. Viruses. 2021, 7NoroSurv: A global network for norovirus strain surveillance – data retrieved on 17 Apr 202
Slide 7: HIL-214 comprises VLPs for major genotypes GI.1 and GII.4
HIL-214 comprises VLPs for major genotypes GI.1 and GII.4 GI.1 selected based on its potential to promote a broad immune response to GI strains GII.4 selected because it is estimated to be responsible for nearly two-thirds of norovirus illness1 1 Virus-Like Particles (VLPs) Consensus GII.4 VLP GI.1
Slide 8: HIL-214 clinical trials overview
Intranasal formulation of vaccine, not included in HIL-214 safety and immunogenicity subject numbers NEST-IN1, NOR-109, NOR-206, and NOR-215 clinical trials ongoing, final subject numbers still estimated for study completion R: randomized. DB: double-blind. OL: open label. Pbo: placebo-controlled Tr
Slide 9: HIL-214 clinical data have de-risked the program
We believe that HIL-214 clinical data have substantially de-risked the program HIL-214 key clinical accomplishments Dose selection Adjuvant selection Immunogenicity in infants/children Immunogenicity in adults/older adults Efficacy proof-of-concept in adults Safety/tolerability profile across age gr
Slide 10: HIL-214 safety profile
SAFETY >6,000 subjects (2,430 pediatric subjects) received vaccine in clinical studies In adults, local AEs all mild/moderate with systemic AEs similar to placebo Infant AEs largely mild to moderate with short duration (<3-4 days) HIL-214 clinical AE profile comparable to commercial vaccines Adult s
Slide 11: HIL-214 immunogenicity
HIL-214 immunogenicity HBGA is an attachment factor on the surface of intestinal epithelia known to promote norovirus entry into host cells Measurement of HBGA-blocking antibodies is the primary method to assess vaccine immunogenicity against norovirus Data from long-term immunogenicity study in adu
Slide 12: Phase 2b adult efficacy: clinical proof of concept
Cases of moderate-to-severe AGE Viral efficacy Pathogen Placebo n = 2,357 HIL-214 n = 2,355 % p value 1° HIL-214 vaccine strain only1 5 (0.2) 1 (<0.1) 80.0 p = 0.142 2° Any NoV strain 26 (1.1) 10 (0.4) 61.8 p = 0.0097 Post-hoc GII.2 strain 21 9 57.4 p = 0.0321 Phase 2b in adults demonstrated reducti
Slide 13: Initial regulatory approach prioritizes infant population
We have prioritized our initial regulatory approach for registration on the infant population Endemic pattern of infection Higher prevalence of GII.4 Comparison to subjects without pre-existing immunity Regulatory and operational precedent of rotavirus vaccines Advantages of studying HIL-214 in infa
Slide 14: NEST-IN1 Phase 2b pediatric study ongoing
NEST-IN1 Phase 2b pediatric study ongoing 1 Vaccinations at Day 1 and Day 29 - 57 HIL-2141 (n = 1,500) Placebo1 (n = 1,500) Primary Endpoint Reduction in moderate/severe acute gastroenteritis associated with norovirus GI.1 or GII.4 (co-pathogen negative) Healthy 5 mo. infants (n = ~3,000) Sites in t
Slide 15: NEST-IN1 has achieved significant milestones
NEST-IN1 has achieved significant milestones since May 2022 initiation NEST-IN1 updates Data Monitoring Committee completed recommended study continuation after safety review in August 2022 First 200 subjects immune responses1 were consistent with prior infant studies of HIL-214 in November 2022 Enr
Slide 16: Other ongoing supporting studies of HIL-214
Other ongoing supporting studies of HIL-214 NOR-109 NOR-215 NOR-206 Study # I II II Phase R, DB, Pbo, safety and immunogenicity SA, OL, safety and immunogenicity R, DB, Pbo, safety and immunogenicity when HIL-214 is concomitantly administered with routine infant vaccines Design Enrollment complete E
Slide 17: Development and regulatory strategy
Development and regulatory strategy Initial clinical program focused on infant population Followed by immuno-bridging and/or efficacy studies in older adults Clinical program and concurrent epidemiology and pharmacoeconomic studies to support potential ACIP recommendations Phase 2b PoC study in infa
Slide 18: Norovirus disease burden compared with other vaccine-preventable viruses
Disease Age US cases US hospitalizations US deaths US economic burden (in 2020 dollars) Norovirus < 4 years 2.8 million 12,000 20 $1.2 billion 5 – 64 years 15.7 million 34,000 70 $6.4 billion > 65 years 3.7 million 50,000 1,250 $3.2 billion All ages 22 million 96,000 1,350 $10.6 billion Rotavirus (p
Slide 19: Potential multi-billion dollar commercial opportunity
Potential multi-billion dollar commercial opportunity Similar burden of disease between norovirus and rotavirus Two rotavirus vaccines were launched in 2006 and 2008 (RotaTeq and Rotarix) ACIP recommendation for routine infant use $1.4B global net sales in 2022 $210-360 per rotavirus vaccine course
Slide 20: HilleVax announces exclusive license with Kangh
HilleVax announces exclusive license with Kangh
Slide 21: Building towards a long-term norovirus vaccine leadership position
Building towards a long-term norovirus vaccine leadership position HIL-216 includes VLPs for six of the most common norovirus genotypes, including GI.1, GII.2, GII.3, GII.4, GII.6, and GII.17 Kangh to supply HIL-216 for use in near-term clinical trials Follow-on hexavalent norovirus vaccine candidat
Slide 22: Anticipated milestones and strong capital position
3Q22 Mid-2024 Phase 2b interim safety results first 200 subjects Anticipated milestones 4Q22 Phase 2b interim immunogenicity results first 200 subjects Phase 2b topline data Strong Capital position As of September 30, 2023: $324.4M cash, cash equivalents & marketable securities1 $75M term loan2: $25
Slide 23: Most advanced norovirus vaccine candidate
Most advanced norovirus vaccine candidate Clinical PoC demonstrated in adults Phase IIb study readout in mid-2024 on 3,000 infants Next gen hexavalent VLP vaccine candidate licensed Large potential commercial opportunity NASDAQ: HLVX